Biology subjects

Rizou, T.

Publications and source records attributed to Rizou, T..

3 recordsLinked to original sources

bioRxiv2026

A combined program of induced stemness and differentiation in response to interferon gamma drives acute myeloid leukaemia growth

How inflammation shapes acute myeloid leukaemia (AML) has come under scrutiny, as it may explain the disease resistance to immunotherapy approaches. IFNg has emerged as a key cytokine with paradoxical roles in suppressing and supporting AML growth, and the fundamental question of how leukemic stem cells (LSCs) respond to IFNg and whether IFNg signaling influences LSC quiescence and their capacity to regenerate disease over the long term remains unanswered. Here, we study primary human AML cells and murine models and combine bioinformatics analyses and functional assays to show that AML hierarchical heterogeneity is responsive to IFNg challenge. We uncover that IFNg triggers parallel stemness and differentiation programs; HSC/MPP-like cells enter deeper stemness, associated with quiescence and high leukaemia regeneration potential, while the surviving pool of progenitor-like cells divides faster but produces progeny that is quickly lost. Finally, with murine models we show that exposure to inflammation in vivo results in only transient impairment of leukaemia propagating capacity. This mechanism is driven by a previously unrecognised intraclonal fate bifurcation, relevant for the development of more effective therapeutic approaches.

cancer biology↗

bioRxiv2026

An injectable soft implant for long-acting, reversible, ultra-stable release of therapeutics

Providing long-term (>6 months) zero-order drug release from easily administered formulations is a key challenge in improving patient adherence and facilitating access. Herein, we report the design and development of an injectable, biodegradable, long-acting polymeric microparticle-embedded hydrogel platform for prolonged, zero-order release of therapeutics. This "soft implant" is injectable for ease of administration and can be retrieved via a small incision, allowing for discontinuation of therapy if desired. Central to the platform are surface-eroding poly(orthoester) (POE) microparticles, which were molecularly tailored to tune zero-order drug release across a wide range of timeframes. We demonstrate the clinical potential of the "soft implant" using levonorgestrel, a contraceptive agent requiring sustained dosing. In vitro, we observed zero-order release for 300 days, projected for >12 months, with behavior consistent with surface erosion further supported through Raman chemical mapping. In vivo studies confirmed zero-order release for six months, projected to 12 months, from a subcutaneous injection in rats. We envision that our platform could transform therapies that require long-term, regular drug dosing, significantly improving compliance and therapy outcomes.

bioengineering↗

bioRxiv2025

Inhibition of neutrophil degranulation by Nexinhib20 delays the development of radiation-induced pulmonary fibrosis

Despite advances in radiation delivery techniques that enhance tumour targeting and minimise collateral exposure, healthy tissues remain susceptible to radiation-induced fibrosis, a chronic and progressive condition that can severely compromise patient quality of life. Therapeutic options to prevent or treat radiation-induced fibrosis remain limited. Recent work has shown that neutrophils infiltrating healthy lung tissue after irradiation adopt an activated phenotype capable of perturbing cellular responses of both epithelial and mesenchymal cells. However, the contribution of these radiation-educated neutrophils to the development of radiation-induced fibrosis remains unclear. Using targeted, image-guided lung irradiation to deliver a dose sufficient to induce fibrosis within four months, we demonstrate that neutrophils are essential for the efficient development of clinically evident fibrosis. Lung irradiation educates neutrophils, enabling them to promote early alterations in the extracellular matrix shortly after radiation exposure. We further show that this "educated" phenotype depends on neutrophil degranulation activity. Pharmacological inhibition of degranulation with Nexinhib20 redirected these cells toward a pro-angiogenic and anti-fibrotic phenotype. Importantly, this treatment was also associated with a transcriptional shift in mesenchymal cells away from a pro-fibrotic program, resulting in a marked delay in the onset of radiation-induced fibrosis. Importantly, Nexinhib20 did not impair the efficacy of cancer radiotherapy, underscoring its potential as a therapeutic strategy to prevent fibrotic complications without diminishing anti-tumour effectiveness.

cancer biology↗